Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.9M
7M shares
52-week range
$0.62 – $6.25
11% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
www.creativemedicaltechnology.comNo one on the platform currently holds CELZ.
No tracked institution reports a position in CELZ as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-06-12 | 1-for-10reverse |
| 2021-11-10 | 1-for-500reverse |
| 2020-02-03 | 1-for-150reverse |
No one on the platform has traded CELZ yet.
Put ticker JUNS onto your watchlist right now! JUNS has only 770k shares outstanding and only 480k shares public float. Look at what SDOT / YXT / DFNS / AKAN did on similar share numbers recently! JUNS has a similar move coming - Added a big position for a squeeze. $DOMH $CELZ News?
View on StockTwits ↗$CELZ Topline results after the special meeting, maybe? They are late according to this.
View on StockTwits ↗$CELZ already has ~9.5M authorized shares available plus $8.7M in cash. If management needs substantially more for Phase 3, a partnership, acquisition, or another identifiable value-creating purpose, why not explain that need and ask shareholders for an appropriately sized authorization? Disclosure rules don't prevent CELZ from providing considerably more context. Management could publicly explain what the additional authorization is primarily intended for and provide estimated capital needs or reasonable dilution guardrails without disclosing confidential counterparties or negotiations. “Additional flexibility to use its capital stock for business and financial purposes in the future” does not come close to cutting it in my book. If Proposal 1 passes, shareholder leverage plummets. And if that enormous new capacity is then used for repeated low-priced financings without corresponding value creation, longs could get THUMPED. VOTE
View on StockTwits ↗$CELZ Come on, throw some coal on the fire; bought another 450 shares yesterday at 1.17. It's not a lot, but it's a done deal.
View on StockTwits ↗$BOXL YOU SHORT IDIOTS DESERVE THIS☝️ $RMCF $CELZ $SOAR take note 📝
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $23M | +780166.7% | $-1.14 | $-1.14–$-1.14 | — | 1 |
| 2027 | $34M | +44.5% | $-0.86 | $-0.86–$-0.86 | — | 1 |
| 2028 | $60M | +77.6% | $-0.83 | $-0.83–$-0.83 | — | 1 |
| 2029 | $85M | +41.9% | $3.94 | $3.94–$3.94 | 0.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-07 | $-0.39 | $-0.41 | -5.1% |
| 2026-05-08 | $-0.39 | $-0.38 | +2.6% |
| 2026-03-20 | $-0.37 | $-0.80 | -116.2% |
| 2025-11-07 | $-0.48 | $-0.48 | +0.0% |
| 2025-08-08 | $-0.63 | $-0.48 | +23.8% |
| 2025-05-09 | $-0.52 | $-0.83 | -59.6% |
| 2025-03-14 | $-0.63 | $-1.12 | -77.8% |
| 2024-11-08 | $-0.85 |
| $-0.75 |
| +11.8% |
| $6M |
| — |
| APREAprea Therapeutics, Inc. | $0.67 | -1.76% | $8M | — |
| BCDABioCardia, Inc. | $0.93 | +5.56% | $14M | — |
Source: Financial Modeling Prep · peers by sector/industry